Market Overview

The sterile injectable contract manufacturing market was valued at USD 24.15 billion in 2025, according to Polaris Market Research. The market is estimated at USD 27.06 billion in 2026 and is projected to reach USD 68.05 billion by 2034, registering a CAGR of 12.2% from 2026 to 2034. The report attributes demand to the rising preference for biologics and biosimilars, along with growing investments in pharmaceutical R&D activities. North America was the largest regional market in 2025.

What Sterile Injectable Contract Manufacturing Involves

Sterile injectable contract manufacturing refers to the outsourcing of injectable drug production to a specialized manufacturer. Medicines are produced under controlled conditions in which the chance of contamination is minimized. Contract manufacturers offer services such as formulation, aseptic filling, quality inspection, packaging and testing for pharmaceutical and biotechnology companies. The process follows controlled stages, including drug formulation, sterile filtration, aseptic fill, closing, lyophilization, quality control testing, packaging and cold chain handling.

Aseptic Fill-Finish as a Core Service

Aseptic fill-finish is the process of filling a sterile drug product into its final container, such as a vial, prefilled syringe or ampoule, under controlled conditions that prevent contamination. By service type, commercial manufacturing led with a 42.15% share in 2025, supported by the continued need for volume production after products are developed and approved. The aseptic fill-finish services segment is expected to grow at an 11.35% CAGR as pharmaceutical companies seek reliable ways to produce sterile injectables without investing heavily in new facilities.

Lyophilization and Product Stability

Lyophilization, or freeze-drying, is used for some drugs to enhance stability in storage. Polaris describes it as the removal of water from biological products at low temperature, extending shelf life, and notes that it is critical for protein biologics and vaccines. The report characterizes lyophilization capacity as established and in high demand. Many leading contract manufacturers profiled in the report list freeze-drying among their capabilities alongside fill-finish and packaging, reflecting how closely the two services are linked.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/sterile-injectable-contract-manufacturing-market 

Finished Drug Product and Large Molecules Lead

The finished drug product segment led with a 63.55% share in 2025, reflecting the continued need to outsource the manufacture of ready-to-use sterile injectable drugs. Contract partners provide filling, packaging and quality control for these products, which helps companies increase production without major facility investments. The API segment is projected to grow at a 10.65% CAGR. By molecule type, large molecules accounted for a 59.65% share in 2025 because of the increasing prevalence of biologics and biosimilars, and these complex therapies require specialized process control and quality management systems. Small molecules are projected to grow at a 10.15% CAGR.

Biosimilars and Patent Expirations

Biologics and biosimilars are a central demand driver. In March 2026, the FDA announced further steps to facilitate biosimilar development and reported that 82 biosimilars had been approved in the U.S. Polaris explains that biosimilar commercialization typically needs specialty manufacturing, especially sterile filling and packaging, so drug manufacturers may outsource to contract organizations with those capabilities. Patent expirations add momentum: Sandoz reported 22% growth in biosimilar sales in the second quarter of 2026, citing major patent expirations as a tremendous opportunity. Companies planning biosimilar commercialization can use contract partners instead of building a complete manufacturing network internally.

Outsourcing and Chronic Disease Demand

Pharmaceutical organizations are increasingly using third-party manufacturers rather than developing internal capabilities. In June 2026, Shantha Biologics entered into an outsourcing arrangement with Novo Nordisk for cartridge fill-finish of injectable medicines in India, covering products such as insulin. Chronic disease also sustains demand. The International Diabetes Federation reports that 589 million adults aged 20 to 79 are living with diabetes, a number predicted to rise to 853 million by 2050, and insulin and other injectable drugs remain effective treatments.

Regional and Therapeutic Highlights

North America held a 36.15% share in 2025 on the strength of its pharmaceutical infrastructure and healthcare spending. In 2025, Jubilant HollisterStier introduced a new high-speed sterile fill-finish isolator line in Spokane, Washington, following a USD 132 million investment that increased the facility's capacity by 50%. Europe held a 28.45% share, and Asia Pacific is projected to grow at a 13.75% CAGR. By therapeutic application, oncology led with a 29.15% share, while CNS diseases are projected to grow at a 14.15% CAGR.

Key Players and Recent Developments

Key players include Aenova Group, Alcami Corporation, Boehringer Ingelheim BioXcellence, Cipla Limited, CordenPharma International, Delpharm, FAMAR Health Care Services, Fresenius Kabi AG, Jubilant HollisterStier, NextPharma Technologies, PCI Pharma Services, Pfizer CentreOne, Recipharm AB, Simtra BioPharma Solutions, Unither Pharmaceuticals, Vetter Pharma-Fertigung GmbH & Co. KG and WuXi Biologics. In April 2026, Adragos Pharma completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi.

Conclusion

The sterile injectable contract manufacturing market is expected to grow from USD 24.15 billion in 2025 to USD 68.05 billion by 2034. As pharmaceutical and biopharmaceutical companies expand biologics pipelines, aseptic fill-finish, lyophilization, finished drug product manufacturing and capacity for large molecules will remain central to how sponsors and their contract partners plan sterile supply.

More Trending Latest Reports By Polaris Market Research:

ai-in-healthcare-market

global-polypropylene-market

us-laundry-detergent-market

global-osteoarthritis-market

security-operation-center-market

global-super-absorbent-polymer-sap-market

examining-leading-top-7-companies-in-the-electric-clothes-dryer-market

food-antioxidants-market

industrial-boiler-market